Evotec, BMS debut program to speed academic translational research

By The Science Advisory Board staff writers

May 7, 2021 -- Evotec announced on May 6 a new program that aims to accelerate translational research from the U.K.'s academic life science ecosystem in collaboration with Bristol-Myers Squibb (BMS).

The company launched beLab1407, a new $20 million program to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the U.K.'s top-tier academic institutions.

The program aims to advance innovation in therapeutics from academia to patient benefit, as well as creating spinout companies in the process.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.